SavedAdd your journal

Journals / Düşünen Adam - Psikiyatri ve Nörolojik Bilimler Dergisi / 2019 / Cilt: 32 - Sayı: 2

Hyponatremia during treatment with the clozapineamisulpride combination: a suspected association and improvement with dose reduction

Mehmet Hamdi ÖRÜM
Behice Han ALMİŞ
Pages
171–174
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, we should not prematurely change the combination of clozapine and amisulpride in treatment-resistant schizophrenia.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Clozapine is the only antipsychotic that is effective in treatment-resistant schizophrenia, but in certain cases its effectiveness is limited.
📊
Key Findings & Data:Here we report for the first time in a 31-year-old male patient diagnosed with schizophrenia who presented with hyponatremia following the addition of amisulpride to clozapine and the improvement of this condition with dose reduction.
💡
Conclusion & Impact:In conclusion, we should not prematurely change the combination of clozapine and amisulpride in treatment-resistant schizophrenia.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Clozapine is the only antipsychotic that is effective in treatment-resistant schizophrenia, but in certain cases its effectiveness is limited. To improve efficacy, clinicians commonly augment clozapine with another antipsychotic. Clozapine has serious side effects due to its receptor profile. The second antipsychotic to be added to clozapine should be less likely to cause these side effects. Amisulpride may be a suitable medication for clozapine-augmentation therapy. However, side effects may also occur in this combination. Here we report for the first time in a 31-year-old male patient diagnosed with schizophrenia who presented with hyponatremia following the addition of amisulpride to clozapine and the improvement of this condition with dose reduction. When adverse effects are non-fatal or can be controlled by supportive treatments, dose reduction may be more useful than discontinuing the drug. In conclusion, we should not prematurely change the combination of clozapine and amisulpride in treatment-resistant schizophrenia.

🔖

Cite This Article

ÖRÜM, M. H., ALMİŞ, B. H. (2019). Hyponatremia during treatment with the clozapineamisulpride combination: a suspected association and improvement with dose reduction. Düşünen Adam - Psikiyatri ve Nörolojik Bilimler Dergisi, Cilt: 32 - Sayı: 2, 171–174. https://ajindex.com/articles/156653

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and metaanalysis of randomized trials. Am J Psychiatry 2001; 158:518-526.
  2. Kampf P, Agelink W, Mass R, Jahn H, Schafer I, Naber D. Amisulpride in addition to clozapine: A retrospective study indicates improved efficacy and good tolerability. German J Psychiatry 2003; 6:64-68.
  3. Barnes TRE, Leeson V, Paton C, Marston L, Osborn DP, Kumar R, Keown P, Zafar R, Iqbal K, Singh V, Fridrich P, Fitzgerald Z, Bagalkote H, Haddad PM, Husni M, Amos T. Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial. Ther Adv Psychopharmacol 2018; 8:185-197. [CrossRef] Ogilvie AD, Croy MF. Clozapine and hyponatremia. Lancet 1992; 340:672. [CrossRef] Collins A, Anderson J. SIADH induced by two atypical antipsychotics. Int J Geriatr Psychiatry 2000; 15:282-283. American Psychiatric Association. Diagnostic and Statistical Manual of Mental disorders Fifth ed. (DSM-5), Washington, DC: American Psychiatric Publ., 2013. [CrossRef] Kose S, Akin E, Cetin M. Adverse drug reactions and causality: The Turkish version of Naranjo Adverse Drug Reactions Probability Scale. Psychiatry and Clinical Psychopharmacology 2017; 27:205-206. [CrossRef] Barnes TRE, Leeson V, Paton C, Marston L, Osborn DP, Kumar R, Keown P, Zafar R, Iqbal K, Singh V, Fridrich P, Fitzgerald Z, Bagalkote H, Haddad PM, Husni M, Amos T. Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial. Ther Adv Psychopharmacol 2018; 8:185-197. [CrossRef] Mannesse CK, van Puijenbroek EP, Jansen PA, van Marum RJ, Souverein PC, Egberts TC. Hyponatraemia as an adverse drug reaction of antipsychotic drugs: a case-control study in VigiBase. Drug Saf 2010; 33:569-578. [CrossRef] Ali SN, Bazzano LA. Hyponatremia in association with secondgeneration antipsychotics: A systematic review of case reports. Ochsner J 2018; 18:230-235. [CrossRef] Gandhi S, McArthur E, Reiss JP, Mamdani MM, Hackam DG, Weir MA, Garg AX. Atypical antipsychotic medications and hyponatremia in older adults: a population-based cohort study. Can J Kidney Health Dis 2016; 3:21. [CrossRef] Orum MH, Kalenderoglu A, Egilmez OB, Ozen ME, Kapici Y. Hyponatremia associated with repeated use of sodium valproate. Psychiatry and Behavioral Sciences 2018; 8:93-94. [CrossRef] Meulendijks D, Mannesse